Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 18
2021 22
2022 23
2023 26
2024 20
2025 21
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Cited In for PMID: 31492652

124 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L; RADIANCE Trial Investigators. Cohen JA, et al. Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3. Lancet Neurol. 2019. PMID: 31492652 Clinical Trial.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Krakovich A, Cheng CY, Riolo JV, Pachai C, Thorpe A, DeBoer E, Kappos L, Cohen JA, Cree BA. Selmaj KW, et al. Mult Scler. 2025 Nov;31(13):1557-1571. doi: 10.1177/13524585251382796. Epub 2025 Nov 5. Mult Scler. 2025. PMID: 41190505 Free PMC article. Clinical Trial.
Case Report: Asymptomatic macular edema in ozanimod.
Mauceri VA, Torresin T, Basili E, Gaggiola M, Rinaldi F, Baroni F, Gallo P, Perini P, Pilotto E, Puthenparampil M. Mauceri VA, et al. Front Ophthalmol (Lausanne). 2025 Oct 7;5:1632065. doi: 10.3389/fopht.2025.1632065. eCollection 2025. Front Ophthalmol (Lausanne). 2025. PMID: 41127406 Free PMC article.
Multiple sclerosis: molecular pathogenesis and therapeutic intervention.
Boutitah-Benyaich I, Eixarch H, Villacieros-Álvarez J, Hervera A, Cobo-Calvo Á, Montalban X, Espejo C. Boutitah-Benyaich I, et al. Signal Transduct Target Ther. 2025 Oct 2;10(1):324. doi: 10.1038/s41392-025-02415-4. Signal Transduct Target Ther. 2025. PMID: 41034190 Free PMC article. Review.
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
Maniscalco GT, Sparaco M, Di Gregorio M, Cafasso G, Signoriello E, Romano F, Iodice R, Fantozzi R, Bellantonio P, Zanghi A, Sinisi L, D'Ambrosio A, Busillo V, Scarano V, Capuano R, Lavorgna L, Williams M, De Martino A, Di Battista ME, Di Giulio Cesare D, Lus G, Cassano E, Di Filippo PS, Sibilia G, Abbadessa G, Andreone V, Bonavita S. Maniscalco GT, et al. J Neurol. 2025 Aug 6;272(9):559. doi: 10.1007/s00415-025-13300-z. J Neurol. 2025. PMID: 40770143 Free PMC article.
124 results